References
- Angelini S, Botticelli A, Onesti CE, et al. (2017). Pharmacogenetic approach to toxicity in breast cancer patients treated with taxanes. Anticancer Res 37:2633–9.
- Balmaceda C. (1998). Advances in brain tumor chemosensitivity. Curr Opin Oncol 10:194–200.
- Ben HI, Gharbi H, Soltani I, et al. (2017). Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia. Cancer Chemother Pharmacol 80:829–39.
- Beuselinck B, Lambrechts D, Van Brussel T, et al. (2014). Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta Oncol 53:1413–22.
- Chu YH, Li H, Tan HS, et al. (2015). Association of ABCB1 and FLT3 polymorphisms with toxicities and survival in Asian patients receiving sunitinib for renal cell carcinoma. PLoS One 10:e0134102.
- Dessilly G, Elens L, Panin N. (2014). ABCB1 1199G.A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. PLoS One 9:1–10.
- Dessilly G, Elens L, Panin N, et al. (2017). ABCB1 1199G > A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib. Pharmacogenomics 7:883–90.
- Dessilly G, Panin N, Elens L, et al. (2016). Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib. Sci. Rep 6:29559–64.
- Geraldine D, Laure E, Nadtha P. (2014). ABCB1 1199G > A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. PLoS One 9:3–13.
- Haufroid V. (2011). Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. Curr Drug Targets 12:631–46.
- Hoffmeyer S, Burk O, von Richter O, et al. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–8.
- Kim HJ, Im SA, Keam B, et al. (2015). ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci 106:86–93.
- Kim RB, Leake BF, Choo EF. (2001). Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–99.
- Polli JW, Wring SA, Humphreys JE, et al. (2001). Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620–8.
- Li YH, Wang YH, Li Y, Yang L. (2006). MDR1 gene polymorphisms and clinical relevance. Yi Chuan Xue Bao 33:93–104.
- Madrid-Paredes A, Cañadas-Garre M, Sánchez-Pozo A, et al. (2017). ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: a meta-analysis. Surg Oncol 26:473–82.
- Watanabe A, Yamamoto K, Ioroi T, et al. (2017). Association of single nucleotide polymorphisms in STAT3, ABCB1, and ABCG2 with stomatitis in patients with metastatic renal cell carcinoma treated with sunitinib: a retrospective analysis in Japanese patients. Biol Pharm Bull 40:458–64.
- Woodahl EL, Yang Z, Bui T, et al. (2005). MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS 19:1617–25.
- Tulsyan S, Mittal RD, Mittal B. (2016). The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment. Pharmgenomics Pers Med 9:47–58.
- Uemura, H, Shinohara, N, Yuasa, T, et al. (2010). A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Japanese Journal of Clinical Oncology 40:194–202. 19897852 10.1093/jjco/hyp146.